TRDA – entrada therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Entrada Therapeutics (NASDAQ:TRDA) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Form 8-K Entrada Therapeutics, For: Jan 08
Form EFFECT Entrada Therapeutics,
Form SCHEDULE 13G Entrada Therapeutics, Filed by: TCG Crossover GP I, LLC
Form 4 Entrada Therapeutics, For: Nov 21 Filed by: WENTWORTH KORY JAMES
Form 4 Entrada Therapeutics, For: Nov 20 Filed by: BAKER BROS. ADVISORS LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.